Oral Cladribine in Patients who Change From First-Line Disease Modifying Treatments for Multiple Sclerosis: Protocol of a Prospective Effectiveness and Safety Study (CLAD CROSS)

BACKGROUND: Recently, the number of available disease modifying therapies for multiple sclerosis (MS) has increased. However, a proportion of patients treated with these agents continue to experience relapses and disease progression. Cladribine tablets, approved in 2017 for highly active relapsing M...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsivgoulis, Georgios, Deftereos, Spyros, Gobbi, Claudio, Gulowsen Celius, Elisabeth, Kulakowska, Alina, Maniscalco, Giorgia, Mendes, Irene, Grigoriadis, Nicolaos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8980423/
https://www.ncbi.nlm.nih.gov/pubmed/35392050
http://dx.doi.org/10.1177/11795735211069441

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8980423/
https://www.ncbi.nlm.nih.gov/pubmed/35392050
http://dx.doi.org/10.1177/11795735211069441

Ejemplares similares